Asher Bio is a company focused on developing cis-targeted immunotherapies that engage two receptors on the same immune cell to provide a new level of selectivity in immune cell activation.

Asher Bio

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio is backed by Third Rock Ventures and is located in South San Francisco. 

Y Combinator

Evan Cheng

Third Rock Ventures

Invus

Boxer Capital

MBC BioLabs

Wellington Management

Alexandria Venture Investments

Logos Capital

Marshall Wace

Mission BioCapital

Janus Henderson Investors

RA Capital Management

Asher Biotherapeutics

Google Maps

Amazon

CrUX Dataset

CrUX Top 50m

Amazon Virginia Region

AWS Global Accelerator

Java EE

Material-UI

Founder, Chief Technology Officer

Andy Yeung

Chief Executive Officer

Craig Gibbs

Owner

Dustin Brown

Founder, CSO

Ivana Djuretic

VP of Finance

Florence Zhu

VP, Business & Commercial Strategy

Sheldon Okada

Interim Head of Data Science

Aaron Arvey

Director Project Management

Aditi Khurana

Director, Clinical Data Management

Aroba Hafeez

Director

Bob Deresiewicz

Jeffrey Tong

Reid Huber

Co-Founder, Chief Scientific Officer

Chief Technology Officer, Founder

Andrea Pirzkall

Chief Medical Officer

Western US Startups with Female Founders

San Francisco Companies With Fewer Than 1000 Employees (Top 10K)

United States Therapeutics Companies (Top 10K)

Biotechnology Companies With Less Than $10M in Revenue (Top 10K)

Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer.

The company was founded in 2019 and headquartered in San Francisco, California.

Series C - Asher Bio

Series B - Asher Bio

Series A - Asher Bio

Pre Seed Round - Asher Bio

San Francisco

California

United States

North America

Asher Bio Closes $55M Series C Financing

Asher Bio closes Series C financing for AB248 | Asher Biotherapeutics posted on the topic

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials

The Week’s 10 Biggest Funding Rounds: Metsera And Rivos Headline A Slow Week

Asher Biotherapeutics: $55 Million Raised To Develop Precisely-Targeted Immunotherapies

Asher Biotherapeutics on LinkedIn: Asher Bio Closes $55 Million Series C Financing to Advance Lead Program… | 16 ...

Philippines

Asia

India

Spain

Europe

Pakistan

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 18, 2024 8:45 AM	e780d12e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 19, 2024 7:17 AM	49f615ef
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	a324e981
crunchbase profile	general	Nov 4, 2024 11:31 AM	e8db5031
li profile	general	Jul 18, 2024 8:45 AM	fbc76a0a
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	143ef4a3
peers	general	Jul 18, 2024 8:45 AM	70616324
news basic	general	Jul 18, 2024 8:45 AM	2f3293b0
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ASHERBIO

Asher Bio